Sign In
Buy MBRX
$0.400
-0.620 (-60.78%)
At Close: Jul 31, 2026
Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know
01:01pm, Wednesday, 17'th Sep 2025
Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
08:45am, Tuesday, 09'th Sep 2025
European expansion in September across Georgia, Italy, Lithuania, Poland, Romania, Spain, and US 13 subjects recruited (treated, enrolled, or screened) Forecasts total recruitment of 20 or more subjec
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
08:30am, Monday, 08'th Sep 2025
Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.
Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds
08:30am, Thursday, 28'th Aug 2025
HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates
Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
09:15am, Thursday, 14'th Aug 2025
– Live video webcast on Wednesday, August 20 th at 2:00 PM ET HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage
Moleculin Reports Second Quarter 2025 Financial Results and Highlights
08:05am, Wednesday, 13'th Aug 2025
- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial - 20+ additional clinical sites in Europe and the US expected to begin recruitment by the end of Q3
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment
08:40am, Wednesday, 06'th Aug 2025
Presented data highlights the potential of Annamycin for treating broad range of human cancers, including high-need oncology indications
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin
08:35am, Wednesday, 30'th Jul 2025
– New patent enhances market position in Europe HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical
Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference
08:45am, Tuesday, 22'nd Jul 2025
– Video webcast now available on-demand HOUSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical compa
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships
08:25am, Thursday, 17'th Jul 2025
40+ year career at Roche founded on dedication to bringing new innovative medicines to patients and making them accessible
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans
08:35am, Wednesday, 09'th Jul 2025
Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial
Moleculin Announces $5.9 Million Public Offering
09:20am, Friday, 20'th Jun 2025
HOUSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates
Moleculin Participates in Virtual Investor “What This Means” Segment
07:45am, Wednesday, 18'th Jun 2025
Watch the “What This Means" segment here
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML
07:30am, Wednesday, 18'th Jun 2025
Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of patients as young as 6 months – younger th
Moleculin Participates in Virtual Investor “What This Means” Segment
09:15am, Wednesday, 11'th Jun 2025
Globally recognized Oncology Key Opinion Leader, Brian Andrew Van Tine, MD, PhD, discusses the positive topline results from the U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment o
